Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Lung05: BL-B01D1 plus PD-1/VEGF bispecific antibody versus chemotherapy plus PD-1/VEGF bispecific antibody in first-line squamous non-small cell lung cancer
CTR20262901Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan, ivonescimab, paclitaxel, carboplatin in Pulmonary squamous cell carcinoma, sponsored by Biokin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
izalontamab brengitecanivonescimabpaclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20262901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262901.